Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 1 | — | — | — | 1 |
Lung neoplasms | D008175 | — | C34.90 | 1 | 1 | — | — | — | 1 |
Drug common name | Defactinib |
INN | defactinib |
Description | Defactinib (INN, codenamed VS-6063) is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors.
|
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CNC(=O)c1ccc(Nc2ncc(C(F)(F)F)c(NCc3nccnc3N(C)S(C)(=O)=O)n2)cc1 |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3137331 |
ChEBI ID | — |
PubChem CID | 25117126 |
DrugBank | DB12282 |
UNII ID | 53O87HA2QU (ChemIDplus, GSRS) |